Aligos Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 5, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 5, 2026

ALGS$2.57-34.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 15. Exhibits, Financial Statement Schedules

(a)

Documents filed as a part of this Annual Report on Form 10-K:

Financial Statements

The following financial statements are included in Part II, Item 8 of this Annual Report on Form 10-K.

All other schedules have been omitted because they are not required, not applicable, or the required information is otherwise included.

The exhibits listed in the Exhibit Index below are filed or incorporated by reference as part of this Annual Report.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.